Biomea Fusion to Participate at Jefferies London Healthcare Conference

Core Insights - Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for diabetes and obesity [3] - The company will participate in the Jefferies London Healthcare Conference on November 17, 2025, including a fireside chat and one-on-one meetings [1] - Biomea's key products include icovamenib, a selective menin inhibitor for diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist for obesity [3] Company Overview - Biomea Fusion aims to address cardiometabolic disorders, which affect nearly half of Americans and one-fifth of the global population [3] - The company's mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions [3]